Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Summary

This manuscript describes how viral vector-mediated local gene delivery provides an attractive way to express transgenes in the central nervous system. The protocol outlines all crucial steps to perform a viral vector injection in the substantia nigra of the rat to develop a viral vector-based animal model for Parkinson's disease.

Abstract

In order to study the molecular pathways of Parkinson's disease (PD) and to develop novel therapeutic strategies, scientific investigators rely on animal models. The identification of PD-associated genes has led to the development of genetic PD models. Most transgenic α-SYN mouse models develop gradual α-SYN pathology but fail to display clear dopaminergic cell loss and dopamine-dependent behavioral deficits. This hurdle was overcome by direct targeting of the substantia nigra with viral vectors overexpressing PD-associated genes. Local gene delivery using viral vectors provides an attractive way to express transgenes in the central nervous system. Specific brain regions can be targeted (e.g. the substantia nigra), expression can be induced in the adult setting and high expression levels can be achieved. Further, different vector systems based on various viruses can be used. The protocol outlines all crucial steps to perform a viral vector injection in the substantia nigra of the rat to develop a viral vector-based alpha-synuclein animal model for Parkinson's disease.

Introduction

To study the pathophysiology of PD and to develop novel therapeutic strategies, there is an urgent need for animal models that closely resemble the neuropathology, physiology and motor symptoms of human PD. The higher the predictive value, the better we can translate new therapies from animal models to patients.

The discovery of alpha-synuclein (α-SYN) as the first PARK gene in 1997 led to the development of the first genetic PD models. Many transgenic mice overexpressing human wild-type (WT) or mutant (A30P, A53T) α-SYN have been generated over the last decade. The levels of α-SYN overexpression have proven to be crucial in the development of the pathology. Also the mouse strain, the presence or absence of endogenous α-SYN and whether the full length or a truncated form is expressed, plays a role (detailed review by Magen and Chesselet¹). Overexpression of both WT and several clinical mutants of human α-SYN in transgenic mice induces pathological accumulation of α-SYN and neuronal dysfunction^2-6. However, until now most transgenic α-SYN mouse models failed to display clear dopaminergic cell loss and dopamine-dependent behavioral deficits.

This hurdle was overcome by direct targeting of the substantia nigra (SN) with viral vectors overexpressing α-SYN. Viral vectors are derived from viruses that can easily infect cells, introduce genetic material into their host genome and force the host cell to replicate the viral genome in order to produce new virus particles. Viruses can be engineered to non-replicating viral vectors that retain their ability to enter cells and introduce genes. By deleting parts of the viral genome and replacing them by the genes of interest, application of the vector will result in a single round infection without replication in the host cell, generally designated as 'transduction'. Viral vectors can be used for both overexpression and gene silencing. The expressed transgene can be a reporter protein (e.g. green fluorescent protein or firefly luciferase)⁷, a therapeutic protein for gene therapy applications^8-10 or, as we will focus on in this paper, a disease-related protein used for disease modeling^11-14.

Viral vector-mediated gene delivery provides an alternative way to express transgenes in the CNS with several advantages. Using local transgene delivery, specific brain regions can be targeted. Further, transgene expression can be induced during adulthood decreasing the risk of compensatory mechanisms during development. Also, models can be created in different species and strains. And finally, different transgenes can easily be combined. Using viral vectors, high transgene expression levels can be achieved, which might be crucial since the disease onset and severity frequently depend on the level of overexpression.

Several vector systems based on different viruses have been developed. The choice of the vector system depends on the size of the gene of interest, the required duration of gene expression, the target cell and biosafety issues. For stable gene transfer in the brain, lentiviral (LV) and recombinant adeno-associated viral (rAAV) vectors are now considered the vector systems of choice since they lead to efficient and long-term gene expression in the rodent brain. For specific targeting of the dopaminergic neurons (DN) of the SN, rAAV vectors have gradually outcompeted LV vectors because of their higher titers and transduction efficiency of DN.

The best α-SYN based rodent models currently available have been developed from a combined approach using newer AAV serotypes (rAAV 1, 5, 6, 7, 8) and optimized vector constructs, titers, and purity^15,16. The vector titer as well as the vector purity directly influences the phenotypic outcome of the model. Excessive vector titers or insufficiently purified vector batches may result in non-specific toxicity. Therefore, appropriate control vectors are indispensable. Considerable time investment in the viral vector production, upscaling, and purification procedures have also proven essential to obtain reproducible and high quality vector batches.

Protocol

All animal experiments are carried out in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) and approved by the Bioethical Committee of the University of Leuven (Belgium).

1. Recombinant AAV Production and Purification

Note: rAAV vector production and purification was performed by the Leuven Viral Vector Core (LVVC) as previously described¹⁷.

1. Briefly, transfect subconfluent low (<50) passage adherent HEK 293T cells using a 25kD linear polyethylenimine 150 nM NaCl transfection solution and three different plasmids in a ratio of 1:1:1 in DMEM medium 2% foetal bovine serum. After 24 hr of incubation at 37 °C in a 5% CO₂, replace the medium with fresh DMEM medium 2% foetal bovine serum.
   Note: The plasmids include the constructs for the AAV7 serotype, the AAV transfer plasmid encoding the human A53T mutant α-SYN under the control of the CMVie enhanced synapsin1 promoter and the pAdvDeltaF6 adenoviral helper plasmid¹⁷.
2. Harvest the medium 5 days after transient transfection and concentrate using tangential flow filtration¹⁷.
3. Purify the rAAV vector particles from the concentrated medium using an iodixanol step gradient¹⁷.
4. Use standard techniques of real-time PCR for genomic copy (GC) determination. In this protocol, a vector titer of 3.0 E11 GC/ml was used to develop an α-SYN based rat model for PD¹⁷.

2. Stereotactic injection of rAAV α-SYN Vector in the SN of the Rat (Figure 2)

1. House eight weeks old female Wistar rats weighing about 200-250 g under a normal 12 hr light/dark cycle with free access to pelleted food and tap water.
2. Submit the rat to intraperitoneal (i.p.) anesthesia containing a mixture of ketamine (60 mg/kg) and medetomidine (0.4 mg/kg). Once the rat is anesthetized and doesn't react when squeezing the different paws, administer a micro-transponder subcutaneously on the back of the rat for further recognition using a micro-transponder implanter. Check if the micro-transponder is positioned correctly and can be read out by the reading device.
3. Cut the hair on top of the scalp. Apply a local anesthetic on both the scalp and the ears. Perform the rest of the surgical procedure under a laminar flow using aseptic techniques.
4. Place the rats in a stereotactic head frame using two ear bars, a mouth and a nose bar. Cover the body of the rat with a paper blanket to avoid a drop in body temperature. Apply an ocular lubricant to prevent the eyes from drying.
5. Disinfect the scalp with jodium 1% in isopropanol 70% and make a small incision in the midline of the scalp. Gently scrape away the membranes on the skull and rinse with saline. Let the skull dry for several minutes. Observe the cranial sutures and the two reference points: Bregma and Lambda.
6. To inject the rAAV vector into the SN, define the coordinates towards Bregma (anteroposterior: 5.3 mm; mediolateral: 2.0 mm and dorsoventral: 7.2 mm calculated from the dura).
   Note: The three dimensional coordinates for each region of interest can be calculated using a stereotaxic atlas of the rat brain, applying Bregma as anatomical reference point.
7. Fill a 10 µl microinjection syringe (30 gauge 20 mm) with rAAV vector and place it in the stereotaxic instrument connected with a motorized microinjection pump. Control the volume by releasing a drop of vector and eliminate in a polyvalent cleaning detergent pH 9 (e.g. RBS).
8. Visually check if the head is fixed straight in the head frame and evaluate the left-right axis. Carefully visually define the anteroposterior and mediolateral coordinates for Bregma and Lambda and measure their height using a 30 gauge 20 mm needle in the dorsoventral arm of the stereotactic frame.
   1. Allow a maximum of 0.3 mm difference in height between Bregma and Lambda. Place the needle back on Bregma and apply the anteroposterior and mediolateral coordinates by moving the anteroposterior and the mediolateral arm of the stereotactic frame.
9. At the place of injection, measure the height of the skull and ensure that it does not differ more than 0.3 mm from the height of Bregma. Drill a hole in the skull with a diameter of approximately 2 mm. Measure the height of the dura, this will serve as a reference to apply the dorsoventral coordinate. Alternatively subtract a fixed thickness for the skull (0.9 mm).
10. Penetrate the dura using a 26 gauge needle and absorb the blood with a sterile tissue. Wait until all bleeding has stopped before proceeding.
11. Slowly insert the 10 µl microinjection syringe pre-loaded with vector solution into the brain to the pre-determined depth (dorsoventral coordinate). Wait 1 min with the needle in place. Inject 3 µl of vector solution (3.0 E11 genome copies/ml (medium vector dose) or 1.0 E12 GC/ml (high vector dose) of rAAV2/7 α-SYN or eGFP control vector) using the motorized microinjection pump with a throughput of 0.25 µl/min.
12. After injection, keep the needle in place for another 5 min before slowly removing it. Stitch the scalp using coated braided polyester 3.0, disinfect with 1% jodium in 70% isopropanol and gently remove the animal from the stereotactic instrument. First loosen the nose and mouth bar, then the two ear bars.
13. To reverse the anesthesia, inject the rat intraperitoneally with 0.5 mg/kg atipamezole and place the rat in a clean cage on a heating plate of 38 °C until it wakes up. Cover the rat with a paper blanket to prevent a drop in body temperature.
14. Provide easy access to food and water for the first hours. Monitor the rat for the first few days. If necessary apply analgesia.
    Note: There is no need to remove the stitches from the skull. After 1-2 weeks the skull is completely repaired and the stiches come loose.

3. Assessment of rAAV2/7 α-SYN Injected Rats Using Non-invasive PET Imaging, Behavioral Tests and Immunohistochemical Analysis

1. To follow up the kinetics of nigrostriatal dopaminergic neurodegeneration non-invasively over time in individual animals, quantify dopamine transporter (DAT) binding using small-animal positron emission tomography (PET) and a tracer of the DA Transporter e.g. [¹⁸F]-FECT¹⁶.
2. To examine whether the level of dopaminergic neurodegeneration is sufficient to induce motor impairments in the rats, subject the rats to the cylinder test to evaluate spontaneous forelimb use.
   1. Place the rat in a 20 cm wide clear glass cylinder and videotape the behavior during vertical movements along the wall and landing after a rear. Score the number of contacts made by each forepaw for a total of 20 contacts. For detailed description of the scoring criteria see Schallert et al.¹⁸ Express the number of impaired forelimb contacts (e.g. left forepaw) as a percentage of total forelimb contacts (left plus right forepaw).
      Note: Non-lesioned control rats using both paws equally should score around 50% in this test.
3. Perform immunohistochemical (IHC) analysis to assess the level of transgene expression and dopaminergic cell loss.
   1. At different end stages, sacrifice the rats with an overdose of sodium pentobarbital (60 mg/kg, i.p.) and perform an intracardial perfusion with cold saline followed by 4% paraformaldehyde in PBS¹⁹. Fixate the brains overnight at 4 °C and cut 50 µm thick coronal brain sections using a vibrating microtome.
   2. Perform IHC staining on free-floating sections using antibodies against α-SYN and tyrosine hydroxylase to analyze α-SYN expression levels and the level of neurodegeneration¹⁶.

Results

The overall scheme of the experiment is depicted in Figure 1

rAAV 2/7-mediated overexpression of A53T α-SYN induces dopamine-dependent motor deficits.
To examine whether the level of α-SYN overexpression is sufficient to induce motor impairments in the rats, we subjected the rats to the cylinder test to evaluate spontaneous forelimb use (Figure 3A). From 3 weeks ...

Discussion

There are several critical steps within the protocol. The vector titer as well as the vector purity directly influences the phenotypic outcome of the model. Excessive vector titers or insufficiently purified vector batches may result in non-specific toxicity. Therefore, the use of high quality vector batches and appropriate control vectors is indispensable. Further, the exact positioning of the rat's head in the stereotaxic frame and the accurate determination of the coordinates is essential in targeting the substant...

Materials

Name	Company	Catalog Number	Comments
Female 8 weeks old Wistar rats	Janvier	/	200-250 g
Ketamine (Nimatek)	Eurovet animal health	804132
Medetomidine (Dormitor)	Orion-Pharma/ Janssen Animal Health	1070-499
Local anesthetic for scalp and ears: Xylocaïne 2% gel	Astrazeneca	0137-547
Terramycine	Pfizer	0132-472
Buprénorphine (Vetergesic)	Ecuphar	2623-627
Jodium 1% isopropanol	VWR	0484-0100
stereotactic head frame	Stoeling	/
Hamilton Syringe (30 gauge -20mm -pst 2)	Hamilton/ Filter Service	7803-07
atipamezole (Antisedan)	Orion-Pharma/Elanco	1300-185
rAAV A53T α-SYN vector	LVVC, KU Leuven	/	https://gbiomed.kuleuven.be/english/research/50000715/laboratory-of-molecular-virology-and-gene-therapy/lvvc/
sodium pentobarbital (Nembutal)	Ceva Santé	0059-444
microtome	Microm	HM650
rabbit polyclonal synuclein Ab	Chemicon	5038	1:5000
rabbit polyclonal TH Ab	Chemicon	152	1:1000
Lutetium oxyorthosilicate detector-based FOCUS 220 tomograph	Siemens/ Concorde Microsystems	/
radioligand: 18F-FECT	In house	/
L-dopa: Prolopa 125	Roche		6mg/kg i.p.
DMEM, Glutamax	Life Technologies	N° 31331-093
Foetal bovine serum	Life Technologies	N° 10270-106
25 kD linear polyethylenimine (PEI)	Polysciences	/
OptiPrep Density Gradient Medium: Iodixanol	Sigma	D1556-250ML
Optimen	Life Technologies	N° 51985-026
Paxinos 1 watston steretactic atlas, fourth Edition	Elsevier	/